Radiopharm Theranostics Past Earnings Performance
Past criteria checks 0/6
Radiopharm Theranostics's earnings have been declining at an average annual rate of -83%, while the Biotechs industry saw earnings growing at 12.6% annually. Revenues have been growing at an average rate of 41.1% per year.
Key information
-83.0%
Earnings growth rate
-43.1%
EPS growth rate
| Biotechs Industry Growth | 9.6% |
| Revenue growth rate | 41.1% |
| Return on equity | -192.3% |
| Net Margin | -778.6% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Radiopharm Theranostics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 6 | -47 | 16 | 0 |
| 30 Sep 23 | 6 | -41 | 16 | 0 |
| 30 Jun 23 | 6 | -35 | 15 | 0 |
| 31 Mar 23 | 5 | -30 | 15 | 0 |
| 31 Dec 22 | 4 | -26 | 14 | 0 |
| 30 Sep 22 | 2 | -28 | 13 | 0 |
| 30 Jun 22 | 0 | -30 | 12 | 0 |
Quality Earnings: RAD is currently unprofitable.
Growing Profit Margin: RAD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if RAD's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare RAD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RAD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.9%).
Return on Equity
High ROE: RAD has a negative Return on Equity (-192.32%), as it is currently unprofitable.